The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...

Sanofi SNY and partner, Alnylam Pharmaceuticals ALNY, announced that the FDA has approved Qfitlia (fitusiran) as the first ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

Qfitlia is the first FDA-approved antithrombin-lowering therapy indicated for routine prophylaxis to prevent or reduce ...

Sanofi's reversible BTK inhibitor rilzabrutinib has gained the US Food and Drug Administration’s (FDA) orphan drug ...

This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...

Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first ...

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.